At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
64Cu-SARTATEdrug
Likely dose
64Cu-SARTATE 60µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II Study
In Brief
A Phase 2 clinical trial evaluating 64Cu-SARTATE for Neuroendocrine Tumors. Completed, enrolled 45 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartMar 2021
Primary CompletionNov 2024
TodayJul 2026
First PostedJun 18, 2020
Enrollment StartMar 2, 2021
Primary CompletionNov 26, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.0 years ago
Interventions
64Cu-SARTATEdrug
64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.